{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:44:46Z","timestamp":1775587486690,"version":"3.50.1"},"reference-count":46,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1536\/ihj.16-607","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T17:23:17Z","timestamp":1516987397000},"page":"154-160","source":"Crossref","is-referenced-by-count":5,"title":["Pravastatin Decreases Infarct Size Induced by Coronary Artery Ischemia\/Reperfusion with Elevated eNOS Expression in Rats"],"prefix":"10.1536","volume":"59","author":[{"given":"He","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Pharmaceutical College, Beihua University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmaceutical College, Beihua University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmaceutical College, Beihua University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmaceutical College, Beihua University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmaceutical College, Beihua University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pharmaceutical College, Beihua University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","unstructured":"1. Tonkin A, Alyward P, Colquhoun D, <i>et al<\/i>. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fonarow GC, Wright RS, Spencer FA, <i>et al<\/i>. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611-6.","DOI":"10.1016\/j.amjcard.2005.04.029"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masuda J, Tanigawa T, Yamada T, <i>et al<\/i>. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015; 56: 278-85.","DOI":"10.1536\/ihj.14-311"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shepherd J, Cobbe SM, Ford I, <i>et al<\/i>. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.","DOI":"10.1056\/NEJM199511163332001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-82.","DOI":"10.1136\/bmj.303.6797.276"},{"key":"6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/01.CIR.93.3.450","volume":"93","year":"1996","unstructured":"6. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996; 93: 450-6.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jones SP, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 2001; 21: 2059-64.","DOI":"10.1161\/hq1201.099509"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Kaneider NC, Reinisch CM, Dunzendorfer S, Meierhofer C, Djanani A, Wiedermann CJ. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001; 158: 23-33.","DOI":"10.1016\/S0021-9150(00)00764-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942: 23-30.","DOI":"10.1016\/S0006-8993(02)02649-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7.","DOI":"10.1016\/S0735-1097(97)00324-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang ZX, Wang CQ, Li XY, <i>et al<\/i>. Changes of naturally occurring CD4 (+) CD25 (+) FOXP3 (+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment. Int Heart J 2015; 56: 163-9.","DOI":"10.1536\/ihj.14-245"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chen J, Nagasawa Y, Zhu BM, <i>et al<\/i>. Pravastatin prevents arrhythmias induced by coronary artery ischemia\/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 2003; 93: 87-94.","DOI":"10.1254\/jphs.93.87"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chen J, Shen H, Nagasawa Y, Mitsui K, Tsurugi K, Hashimoto K. Pravastatin inhibits arrhythmias induced by coronary artery ischemia in anesthetized rats. J Pharmacol Sci 2007; 103: 317-22.","DOI":"10.1254\/jphs.FP0061235"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Szymanski FM, Karpinski G, Platek AE, <i>et al<\/i>. Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol 2014; 72: 339-44.","DOI":"10.5603\/KP.a2013.0284"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003; 35: 185-93.","DOI":"10.1016\/S0022-2828(02)00310-3"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lawson CS, Coltart DJ, Hearse DJ. &quot;Dose&quot; -dependency and temporal characteristics of protection by ischaemic preconditioning against ischaemia-induced arrhythmias in rat hearts. J Mol Cell Cardiol 1993; 25: 1391-402.","DOI":"10.1006\/jmcc.1993.1156"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Walker MJ, Curtis MJ, Hearse DJ, <i>et al<\/i>. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 1988; 22: 447-55.","DOI":"10.1093\/cvr\/22.7.447"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H59-64.","DOI":"10.1152\/ajpheart.00782.2002"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rani N, Bharti S, Manchanda M, <i>et al<\/i>. Regulation of heat shock proteins 27 and 70, p-Akt\/p-eNOS and MAPKs by Naringin Dampens myocardial injury and dysfunction in vivo after ischemia\/reperfusion. PLoS One 2013; 8: e82577.","DOI":"10.1371\/journal.pone.0082577"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Priori SG, Aliot E, Blomstrom-Lundqvist C, <i>et al<\/i>. Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations. Ital Heart J Suppl 2002; 3: 1051-65.","DOI":"10.1053\/eupc.2001.0214"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993; 119: 1187-97.","DOI":"10.7326\/0003-4819-119-12-199312150-00006"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Struthers AD. Pathophysiology of heart failure following myocardial infarction. Heart 2005; 91 (Suppl 2): ii14-6; discussion ii31, ii43-8.","DOI":"10.1136\/hrt.2005.062034"},{"key":"23","unstructured":"23. Yang Q, He GW, Underwood MJ, Yu CM. Cellular and molecular mechanisms of endothelial ischemia\/reperfusion injury: perspectives and implications for postischemic myocardial protection. Am J Transl Res 2016; 8: 765-77."},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-14.","DOI":"10.1161\/CIRCULATIONAHA.105.602532"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kooijman M, Thijssen DH, de Groot PC, <i>et al<\/i>. Flow-mediated dilatation in the superficial femoral artery is nitric oxide mediated in humans. J Physiol 2008; 586: 1137-45.","DOI":"10.1113\/jphysiol.2007.145722"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Atochin DN, Huang PL. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflugers Arch 2010; 460: 965-74.","DOI":"10.1007\/s00424-010-0867-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Brunner F, Maier R, Andrew P, Wolkart G, Zechner R, Mayer B. Attenuation of myocardial ischemia\/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 2003; 57: 55-62.","DOI":"10.1016\/S0008-6363(02)00649-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia\/reperfusion injury. Cardiovasc Res 2004; 61: 402-13.","DOI":"10.1016\/j.cardiores.2003.09.019"},{"key":"29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/01.CIR.86.1.279","volume":"86","year":"1992","unstructured":"29. Weyrich AS, Ma XL, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation 1992; 86: 279-88.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1161\/01.CIR.101.23.2742","volume":"101","year":"2000","unstructured":"30. Kanno S, Lee PC, Zhang Y, <i>et al<\/i>. Attenuation of myocardial ischemia\/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation 2000; 101: 2742-8.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Xi L, Jarrett NC, Hess ML, Kukreja RC. Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice. Circulation 1999; 99: 2157-63.","DOI":"10.1161\/01.CIR.99.16.2157"},{"key":"32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.CIR.93.2.356","volume":"93","year":"1996","unstructured":"32. Node K, Kitakaze M, Kosaka H, <i>et al<\/i>. Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. Circulation 1996; 93: 356-64.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Balligand JL, Kobzik L, Han X, <i>et al<\/i>. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 1995; 270: 14582-6.","DOI":"10.1074\/jbc.270.24.14582"},{"key":"34","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/01.CIR.92.8.2198","volume":"92","year":"1995","unstructured":"34. Hare JM, Loh E, Creager MA, Colucci WS. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995; 92: 2198-203.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Egashira K, Hirooka Y, Kai H, <i>et al<\/i>. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.","DOI":"10.1161\/01.CIR.89.6.2519"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-41.","DOI":"10.1016\/S0735-1097(98)00514-2"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-71.","DOI":"10.1016\/S0140-6736(95)91322-X"},{"key":"38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","volume":"95","year":"1997","unstructured":"38. O&apos;Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Andreadou I, Farmakis D, Prokovas E, <i>et al<\/i>. Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res 2012; 94: 501-9.","DOI":"10.1093\/cvr\/cvs121"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Fan Y, Yang S, Cao Y, Huang Y. Effects of acute and chronic atorvastatin on cardioprotection of ischemic postconditioning in isolated rat hearts. Cardiovasc Ther 2013; 31: 187-92.","DOI":"10.1111\/j.1755-5922.2012.00318.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kocsis GF, Pipis J, Fekete V, <i>et al<\/i>. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008; 294: H2406-9.","DOI":"10.1152\/ajpheart.00862.2007"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: H343-51.","DOI":"10.1152\/ajpheart.01350.2007"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Tian Y, Linden J, French BA, Yang Z. Atorvastatin at reperfusion reduces myocardial infarct size in mice by activating eNOS in bone marrow-derived cells. PLoS One 2014; 9: e114375.","DOI":"10.1371\/journal.pone.0114375"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Chen Y, Meng G, Bai W, <i>et al<\/i>. Aliskiren protects against myocardial ischaemia-reperfusion injury via an endothelial nitric oxide synthase dependent manner. Clin Exp Pharmacol Physiol 2017; 44: 266-74.","DOI":"10.1111\/1440-1681.12692"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Bao N, Ushikoshi H, Kobayashi H, <i>et al<\/i>. Simvastatin reduces myocardial infarct size via increased nitric oxide production in normocholesterolemic rabbits. J Cardiol 2009; 53: 102-7.","DOI":"10.1016\/j.jjcc.2008.09.012"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Di Napoli P, Antonio Taccardi A, Grilli A, <i>et al<\/i>. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001; 51: 283-93.","DOI":"10.1016\/S0008-6363(01)00306-6"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/1\/59_16-607\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T17:35:14Z","timestamp":1570642514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/1\/59_16-607\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.16-607","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}